Recombinant human fibroblast growth factor and autogenous bone for periodontal regeneration: Alone or in combination? A randomized clinical trial
Journal of Periodontal Research · 2024
DOI: 10.1111/jre.13310 ↗Kurz gefasst
Randomisierte kontrollierte Studie in der Zeitschrift Journal of Periodontal Research, 2024. Verfasst von Kosuke Kojima und 13 weiteren Autor:innen. Beteiligte Einrichtung: Department of Implantology and Periodontology, Graduate School of Dentistry, Kanagawa Dental University, Yokohama, Kanagawa, Japan. Hauptthemen laut MEDLINE: Fibroblast Growth Factor 2, Recombinant Proteins, Alveolar Bone Loss, Guided Tissue Regeneration, Periodontal. Die Arbeit wurde bisher 22-mal zitiert (Crossref) und nennt 48 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0).
Abstract (Originalsprache)
Aim
To compare the outcomes of therapy using recombinant human fibroblast growth factor (rhFGF)‐2 combined with autologous bone grafting (ABG) therapy with those of rhFGF‐2 alone and ABG alone in the treatment of periodontal intraosseous defects.
Methods
Periodontal intraosseous defects were randomized to receive rhFGF‐2 therapy + ABG, rhFGF‐2 therapy alone, or ABG alone. Periodontal examination and periapical radiography were performed preoperatively and at 3, 6, and 12 months postoperatively.
Results
At the 12 months follow‐up, all three groups showed significant improvement in the clinical attachment level (CAL): 5.6 ± 1.6, 5.8 ± 1.7, and 5.2 ± 1.6 mm in the rhFGF‐2 + ABG, rhFGF‐2 alone, and ABG alone groups, respectively, with no significant inter‐group differences ( p < .05). rhFGF‐2 therapy (alone or in combination) resulted in greater bone defect filling (BDF) (2.3 ± 1.2 mm and 2.6 ± 1.9 mm, respectively) than ABG therapy alone (1.2 ± 1.2 mm). Gingival recession was lesser in the ABG alone (1.2 ± 1.1 mm) and rhFGF‐2 + ABG groups (1.4 ± 0.8 mm) than in the rhFGF‐2 alone group (2.2 ± 1.2 mm).
Conclusion
The results of this study showed that at 12 months postoperatively, all treatments resulted in statistically significant clinical improvements compared to the baseline. From these results, it can be concluded that rhFGF‐2 promotes hard tissue regeneration in intraosseous defects.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Implantology and Periodontology, Graduate School of Dentistry, Kanagawa Dental University, Yokohama, Kanagawa, Japan.
- Department of Education Planning, Kanagawa Dental University, Yokosuka, Japan.
- Bunkyodori Dental Clinic, Chiba, Japan.
- Department of Gastroenterology, International University Health and Welfare Graduate School of Medicine, Chiba, Japan.
- Department of Biostatistics, JORTC Data Center 2-54-6-302, Tokyo, Japan.
ORCID-Profile: Yohei Kamata
Zitieren
APA
Kojima, K., Kamata, Y., Shimizu, T., Sato, S., Suzuki, S., Takanashi, Y., Hojo, S., Yoshino, T., Fuchida, S., Tamura, T., Minabe, M., Kodama, T., Kessoku, T., & Oyamada, S. (2024). Recombinant human fibroblast growth factor and autogenous bone for periodontal regeneration: Alone or in combination? A randomized clinical trial. Journal of Periodontal Research. https://doi.org/10.1111/jre.13310
Vancouver
Kojima K, Kamata Y, Shimizu T, Sato S, Suzuki S, Takanashi Y, et al. Recombinant human fibroblast growth factor and autogenous bone for periodontal regeneration: Alone or in combination? A randomized clinical trial. Journal of Periodontal Research. 2024. doi:10.1111/jre.13310
BibTeX
@article{Kojima2024,
author = {Kojima, Kosuke and Kamata, Yohei and Shimizu, Tomoko and Sato, Satsuki and Suzuki, Sota and Takanashi, Yuya and Hojo, Sawako and Yoshino, Takeshi and Fuchida, Shinya and Tamura, Toshiyuki and Minabe, Masato and Kodama, Toshiro and Kessoku, Takaomi and Oyamada, Shunsuke},
title = {Recombinant human fibroblast growth factor and autogenous bone for periodontal regeneration: Alone or in combination? A randomized clinical trial},
journal = {Journal of Periodontal Research},
year = {2024},
doi = {10.1111/jre.13310}
}
EUVIMED